Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alessandro Mattina has a total of 273 co-authors. Here are the top co-authors by number of shared publications:

  • Silvio Buscemi

    Department of Promozione della Salute, Materno-Infantile, Medicina Interna e Specialistica di Eccellenza (PROMISE), University of Palermo, Palermo, Italy

    16 shared publications
  • Salvatore Verga

    Dipartimento di Medicina Interna, Malattie Cardiovascolari e NefroUrologiche; Facoltà di Medicina, University of Palermo, Palermo, Italy

    14 shared publications
  • Antonio Gallo

    Department of Nutrition, Sorbonne Université, Inserm UMR1166, IHU-ICAN, Lipidology and Cardiovascular Prevention Unit, AP-HP, Hôpital Pitié Salpètriêre, Paris, France

    8 shared publications
  • Giulio Geraci

    Department of Medicine and Surgery, “Kore” University of Enna, 94100 Enna, Italy

    7 shared publications
  • X. Girerd

    Preventive Cardiovascular Unit, Institute of Cardiometabolism and Nutrition, Unité de Prévention Cardiovasculaire, Service d'Endocrinologie Métabolisme, Groupe Hospitalier Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, 83, boulevard de l'Hôpital, 75651 Paris cedex 13, France

    6 shared publications
  • D. Rosenbaum

    Department of Endocrinology and Cardiovascular Disease Prevention, La Pitié-Salpêtrière-Charles Foix University Hospital (AP-HP), 48-83 boulevard de l'Hôpital, 75651 Paris Cedex 13, France; Sorbonne University, UPMC Univ Paris 06, INSERM 1146, - CNRS 7371, Laboratoire d'imagerie Biomédicale, 91 boulevard de l'Hôpital, 75013, Paris, France; Imaging Core Lab, Institute of Cardiometabolism and Nutrition, ICAN, 48-83 boulevard de l'Hôpital, 75651 Paris Cedex 13, France

    5 shared publications

Latest Publications

  • Open Access

    Personalized Medicine for the Management of Non-Communicable Diseases (NCDs)

    by Alessandro Mattina, Giulio Geraci, Vincenzina Lo Re

    Non-communicable diseases (NCDs) are the leading cause of death worldwide and are among the major drivers of healthcare expenditure, particularly in societies undergoing progressive population aging

  • Open Access

    Advanced Functional Wound Dressings in Precision Surgery: Immunometabolic Reprogramming, Bioadaptive Biomaterials, and Intelligent Regenerative Interfaces

    by Tomasz Urbanowicz, Alessandro Mattina, Judyta Cielecka-Piontek, Giuseppe Maria Raffa, Calogera Pisano, Ewelina Grywalska, Anna Hymos, Mansur Rahnama, Mariusz Kowalewski, Piotr Suwalski, et al.

    Postoperative wound complications remain a major cause of morbidity, prolonged hospitalization, increased healthcare costs, and reduced quality of life. While traditional wound dressings functioned primarily as passive barriers against contamination and exudate, advances in wound biology have transformed surgical wound management. Tissue repair is now recognized as a dynamic immunometabolic process involving coordinated interactions among immune cells, stromal populations, extracellular matrix remodeling, mechanotransduction, mitochondrial function, redox balance, microbial ecology, and bioelectrical signaling. Consequently, modern wound dressings are increasingly designed as bioactive systems capable of actively modulating the wound microenvironment. Recent developments in biomaterials science, immunoengineering, nanotechnology, extracellular vesicle biology, bioelectronics, and artificial intelligence have enabled the creation of advanced wound platforms, including stimuli-responsive hydrogels, immunomodulatory biomaterials, nanozyme-based dressings, conductive scaffolds, oxygen-generating matrices, extracellular vesicle-loaded systems, and biosensor-integrated interfaces. Therapeutic strategies are progressively shifting from antimicrobial-focused approaches toward immune-regenerative modulation targeting chronic inflammation, mitochondrial dysfunction, ferroptosis, cellular senescence, and impaired mechanobiological signaling. This review examines emerging surgical wound dressings from mechanistic, translational, and biomaterial perspectives, highlighting current innovations, translational challenges, and future directions. Collectively, these technologies may enable intelligent therapeutic systems capable of sensing and directing tissue regeneration in real time.


  • Open Access

    The Cardiovascular Burden of Diabetes: Risk Factors, Clinical Phenotypes, and Personalized Cardiometabolic Management

    by Giuliano Cassataro, Giulio Geraci, Maria Ausilia Giusti, Carlo Maida, Viviana Maggio, Manfredi Rizzo, Alessandro Mattina

    Type 2 diabetes (T2D) exhibits substantial phenotypic heterogeneity, resulting in diverse cardiovascular (CV) outcomes driven by multiple pathophysiological mechanisms beyond hyperglycemia alone. T2D should be recognized as a systemic cardiometabolic condition in which insulin resistance, chronic inflammation, oxidative stress, and endothelial and microvascular dysfunction promote a broad spectrum of cardiovascular diseases. The traditional “one-size-fits-all” approach to cardiovascular risk management has been proven insufficient, as individuals with T2D display marked variability in clinical presentation, disease trajectory, treatment response, and cardiovascular phenotype. In this context, personalized medicine strategies integrating clinical phenotyping, individualized risk stratification, and tailored therapeutic interventions offer the potential to optimize cardiometabolic outcomes while minimizing treatment burden and adverse effects. This narrative review examines the rationale and current evidence supporting personalized cardiovascular risk management in T2D. We discuss the heterogeneity of diabetes-related CV phenotypes, encompassing both atherosclerotic and non-atherosclerotic complications. We further examine the major cardiometabolic risk factors closely linked to diabetes, including dyslipidemia, hypertension, obesity, chronic kidney disease, and metabolic liver disease, which act synergistically to accelerate vascular damage and end-organ injury, and are essential for defining personalized prognostic and therapeutic programs. Finally, we present structured approaches to cardiovascular assessment and highlight contemporary management strategies that prioritize integrated, phenotype-driven risk reduction using cardioprotective glucose-lowering therapies together with optimized lipid-lowering, antihypertensive, antithrombotic, and weight-modifying interventions. The transition from population-based guidelines to individualized, patient-centered care represents a paradigm shift in diabetes management, with the potential to substantially reduce the excess CV burden associated with this condition.


  • Open Access

    Thyroid function and liver fibrosis: FT3 levels are inversely and independently correlated with enhanced liver fibrosis score in solid organ transplant patients with dysglycemia

    by Claudia Leanza, Maria Ausilia Giusti, Vitale Miceli, Giovanni Zito, Rosaria Tinnirello, Gioacchin Iannolo, Antonio Galante, Fabrizio Emanuele, Marco Amato, Giovanna Lo Iacono, et al.

    Background: Solid organ transplantation (SOT) is frequently complicated by dysglycemia and metabolic dysfunction–associated steatotic liver disease (MASLD), conditions that accelerate the development of liver fibrosis. Given the recognized thyroid–liver crosstalk, we investigated the association between thyroid function and the enhanced liver fibrosis (ELF) score in SOT recipients with diabetes or prediabetes. Methods: Seventy-one adult SOT recipients with diabetes or prediabetes, with ultrasound evidence of liver steatosis and/or a FIB-4 > 1.3, underwent standardized clinical phenotyping, biochemical profiling, thyroid hormone measurements, ELF testing, and liver stiffness measurement (LSM). Associations with ELF were assessed using correlation analyses and multivariable linear regression adjusted for age, sex, body mass index (BMI), transaminases, glycated haemoglobin, creatinine, haemoglobin, albumin, immunosuppressive drugs, glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy, and transplanted organ type. Results: Participants had a mean age of 63.1 ± 9.5 years and BMI of 27.8 ± 4.8 kg/m². Mean ELF was 9.21 ± 1.00 (low risk <9.8: 70%; intermediate 9.8–11.3: 27%; high ≥11.3: 3%). ELF correlated positively with age (r=0.43, p=0.0002), aspartate aminotransferase (AST; r=0.50, p<0.0001), alanine aminotransferase (ALT; r=0.33, p=0.0059) and creatinine (r=0.39, p=0.0009), and inversely with haemoglobin (r=−0.39, p=0.0009), albumin (r=−0.38, p=0.0024), controlled attenuation parameter (CAP) (r=−0.29, p=0.0171). Among thyroid variables, free triiodothyronine (FT3) correlated inversely with ELF score (r=−0.45, p=0.0003), while TSH and FT4 showed no significant association with ELF score (r=0.00, p=0.9859; r=-0.5, p=0.6891). In multivariable analysis (R²=0.67; p=0.0002), lower FT3 (β=−0.611 ± 0.288; p=0.0404) and age (β=0.029 ± 0.012; p=0.0304) remained independently associated with higher ELF. No association was found between ELF and LSM. Conclusions: In SOT recipients with dysglycemia lower FT3 levels were independently associated with increased ELF scores. This finding suggests a potential link between subtle variations in thyroid function and markers of fibrogenic activity in metabolically vulnerable transplant recipients. Prospective studies are warranted to elucidate the causal directionality of this association and its clinical relevance.


  • P-10: STRUCTURAL AND FUNCTIONAL PRELIMINARY ASSESSMENT OF AN ENCAPSULATION DEVICE FOR Β-CELLS SPHEROIDS USING A SEMIPERMEABLE MEMBRANE

    by Vitale Miceli, Salvatore Castelbuono, Nicola Cuscino, Giovanni Zito, Claudio Centi, Rosaria Tinnirello, Maura Cimino, Massimo Pinzani, Pier Giulio Conaldi, Alessandro Mattina

  • Renal Resistive Index and 10-Year Risk of Cardiovascular Disease Predicted by Framingham Risk Score and Pooled Cohort Equations: An Observational Study in Hypertensive Individuals Without Cardiovascular Disease

    by Giulio Geraci, Alessandra Sorce, Luca Zanoli, Vincenzo Calabrese, Giuseppe Cuttone, Alessandro Mattina, Pietro Ferrara, Ligia J. Dominguez, Riccardo Polosa, Giuseppe Mulè, et al.

    Introduction The renal resistive index (RRI) has been widely shown to be related with subclinical vascular damage in individuals with essential hypertension, as well as in other populations. However, limited data exist regarding the association between RRI and cardiovascular (CV) events in hypertensive individuals. Additionally, it is unclear whether the 10-year risk of CV disease, as predicted by validated score equations, is associated with impaired intrarenal hemodynamics. Aim The aim of our study was to analyze the relationship between RRI and both the FS and ASCVD in hypertensive individuals with no history of CV events. Methods A total of 742 individuals with essential hypertension (40–75 years) were enrolled. RRI was assessed in all patients using Duplex–Doppler ultrasonography, and the 10-year risk of cardiovascular disease was calculated using both the Framingham risk score (FS) and atherosclerotic cardiovascular disease risk score (ASCVD) through validated equations. Results Higher RRI values were observed in patients with calculated CV risk ≥ 20% compared to those with lower risk (all p < 0.001). RRI was closely associated with both FS and ASCVD scores in the overall cohort (all p < 0.001), with no significantly differences between groups with glomerular filtration rate ≥ or < 60 mL/min/1.73m2. In multivariate analyses, these associations remained significant after adjusting for traditional risk factors included in the FS and ASCVD equations (p = 0.007 and p = 0.047, respectively). Receiver-operating characteristic curves indicated that RRI values >0.67 and >0.65 were associated with a high CV risk (≥ 20%), as calculated through FS and ASCVD equations, respectively. Conclusion RRI can be considered a marker of overall CV risk in hypertensive patients, independent of renal function. Graphical Abstract


  • Open Access

    A Bioartificial Device for the Encapsulation of Pancreatic β-Cells Using a Semipermeable Biocompatible Porous Membrane

    by Nicola Cuscino, Salvatore Castelbuono, Claudio Centi, Rosaria Tinnirello, Maura Cimino, Giovanni Zito, Andrea Orlando, Massimo Pinzani, Pier Giulio Conaldi, Alessandro Mattina, et al.

    Background/Objectives: Type 1 diabetes (T1D) is a chronic autoimmune condition characterized by the destruction of pancreatic β-cells, leading to insulin deficiency. Current therapies, such as islet transplantation, face significant challenges, including limited donor availability and the need for lifelong immunosuppression. Encapsulation technologies offer a promising alternative, providing immune protection and maintaining β-cell viability. In this study, we propose an encapsulation device featuring a spiral tubular semipermeable polyethersulfone (PES) membrane reinforced with a rigid biocompatible resin scaffold. Methods: The PES membrane was engineered with a tailored porosity of 0.5 µm, enabling efficient nutrient and oxygen exchange while preventing immune cell infiltration. Using INS-1E insulin-secreting cells aggregated into size-controlled islet-like spheroids (ILSs), we evaluated the device’s performance. Results: The device achieved high ILS viability and insulin secretion over 48 h at therapeutic densities, maintaining functionality comparable to free-floating ILSs (control). The PES membrane, with its mechanical stability and biocompatibility, ensured durability without compromising diffusion dynamics, overcoming a critical limitation of other encapsulation approaches. Importantly, the device geometry allowed for the encapsulation of up to 356,000 islet equivalents (IEQs) in a single capillary fiber, reaching therapeutic thresholds for T1D patients. Conclusions: this device, with its innovative design, enables high-density encapsulation while preserving ILS functionality and scalability, making it a potential platform for clinical application. This work highlights the potential of PES-based encapsulation devices to overcome key barriers in T1D treatment, paving the way for personalized, long-term solutions to restore insulin independence.


  • Open Access

    Coronary Artery Calcium Is Independently Associated with Arterial Stiffness and LDL Cholesterol Burden in Patients with Familial Hypercholesterolemia

    by Alessandro Mattina, Antonina Giammanco, Davide Noto, Giulio Geraci, Emilio Nardi, Carlo Maria Barbagallo, Carola Maria Gagliardo, Maria Ausilia Giusti, Francesco D’ignoto, Francesco Giallauria, et al.

    Background: Familial hypercholesterolemia (FH) is a genetic disorder characterized by high plasma levels of low-density lipoprotein cholesterol (LDL-C) and exposing patients to higher risk of early cardiovascular (CV) atherosclerotic diseases. Though the estimated prevalence of heterozygous FH (HeFH) is about 1 in 200, FH is still underdiagnosed and undertreated. Coronary artery calcification (CAC) assessment and arterial stiffness measured as pulse wave velocity (PWV) have demonstrated their accuracy in CV risk assessment, but data on HeFH are lacking. This study aims to evaluate CAC and PWV in a population of HeFH patients to improve risk stratification and therapy timing and setting. Methods: One hundred genetically characterized HeFH patients, regularly followed up since diagnosis, were recruited at our outpatient clinic. In all patients, CAC, PWV measurement, and LDL-C burden calculation were assessed. Results: The mean age was 45 ± 16 years. A total of 25% of patients had hypertension, and 15% were in secondary prevention. Through univariate analysis, we found strong positive correlations between CAC and both PWV (r = 0.52 p > 0.0001) and total LDL-C burden (r = 0.52 p < 0.0001). No other associations with lipid parameters were found. Multivariate analysis showed that CAC was independently associated with PWV adjusted for sex, total LDL-C burden, systolic blood pressure, smoking, LDL-C, HDL-C, and statin treatment. Conclusions: Arterial stiffness is strongly associated with CAC in HeFH patients with similar total LDL-C burden and CV risk profiles. Personalized risk assessment based on arterial stiffness and CAC evaluation enhances the stratification and management of cardiovascular risk in FH patients, supporting individualized therapeutic approaches.